Mobile

A randomised, double blind, placebo-controlled, multi-centre study to evaluate the efficacy and safety of bevacizumab in combination with docetaxel compared with docetaxel plus placebo, as first line ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-003862-40

A randomised, double blind, placebo-controlled, multi-centre study to evaluate the efficacy and safety of bevacizumab in combination with docetaxel compared with docetaxel plus placebo, as first line treatment for patients with HER2 negative metastatic breast cancer

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare Progression Free Survival (PFS) in patients randomised to • bevacizumab 7.5 mg/kg and docetaxel 100 mg/m[2] q3wk versus docetaxel 100 mg/m[2] and bevacizumab placebo q3wk or • bevacizumab 15 mg/kg and docetaxel 100 mg/m[2] q3wk versus docetaxel 100 mg/m[2] and bevacizumab placebo q3wk

Critère d'inclusion

  • Metastatic breast cancer

Liens